LogoLogoMSF Science Portal
  • My saved items
logo

© Médecins Sans Frontières

MSF Science Portal
About MSF Science Portal
About MSF
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use

v2.1.4829.produseast1

Journal Article > Research

The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study

Abongomera C, Diro EGJ, de Lima Pereira A, Buyze J, Stille K, van Griensven J, Ritmeijer KKD
Download
Download
Abstract
North-west Ethiopia faces the highest burden world-wide of visceral leishmaniasis (VL) and HIV co-infection. VL-HIV co-infected patients have higher (initial) parasitological failure and relapse rates than HIV-negative VL patients. Whereas secondary prophylaxis reduces the relapse rate, parasitological failure rates remain high with the available antileishmanial drugs, especially when administered as monotherapy. We aimed to determine the initial effectiveness (parasitologically-confirmed cure) of a combination of liposomal amphotericin B (AmBisome) and miltefosine for treatment of VL in HIV co-infected patients.
Countries
Ethiopia
Subject Area
tuberculosisHIV/AIDS
DOI
10.1371/journal.pntd.0006527
Published Date
25-May-2018
PubMed ID
29799869
Languages
English
Journal
PLOS Neglected Tropical Diseases
Volume / Issue / Pages
Volume 12, Issue 5
Issue Date
25-May-2018
Dimensions Badge